Antibodies to the N-Terminal Domain of Angiotensin-Converting Enzyme (ACE2) That Block Its Interaction with SARS-CoV-2 S Protein

Dokl Biochem Biophys. 2022 Feb;502(1):1-4. doi: 10.1134/S160767292201001X. Epub 2021 Dec 4.

Abstract

SARS-CoV-2 is a new coronavirus that is the cause of COVID-19 pandemic. To enter the cell, the virus interacts via its surface S protein with angiotensin-converting enzyme 2 (ACE2), the main entry receptor on the cell membrane. Most of protective antibodies, including those induced by vaccinations, target the S protein, preventing its interaction with the ACE2 receptor. We have evaluated an alternative strategy for blocking the S-ACE2 interaction using new antipeptide antibodies to the N-terminus of the ACE2 molecule. These antibodies allow detection of human ACE2 in vitro and ex vivo.

Keywords: COVID-19; peplomers; peptides; receptor.

MeSH terms

  • Angiotensin-Converting Enzyme 2 / immunology*
  • Angiotensins / metabolism
  • COVID-19*
  • Humans
  • Pandemics* / prevention & control
  • Protein Binding
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus

Substances

  • Angiotensins
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2